시장보고서

상품코드

1646513

세계의 항체 약물 접합체 시장 규모와 예측(2021-2031년) : 점유율, 동향, 성장 기회 - 분석 범위(기술별, 용도별, 표적별, 유통 채널별, 지역별)

Antibody Drug Conjugates Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Target, Distribution Channel, and Geography

발행일: 2024년 12월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 286 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항체 약물 접합체 시장은 2023년의 81억 달러에서 2031년에는 380억 7,000만 달러에 이를 것으로 예상되며, 2023년에서 2031년의 CAGR은 21.3%로 추정됩니다. 시장 성장을 견인하는 주요 요인으로는 주요 기업의 전략적 투자, 승인 제품 증가 등이 있습니다. 또한 새로운 적응증으로의 확대가 예측 기간 동안 시장을 밀어 올릴 것으로 보입니다. 그러나 제조 과제는 시장 저해 요인 중 하나입니다.

항체 약물 접합체(antibody-drug conjugates) 시장의 주요 기업에 의한 합병, 인수, 제휴, 공동 연구 등의 주요 투자는 시장의 성장과 개척에 크게 영향을 미칩니다. 이러한 전략을 통해 각 회사는 자원을 모으고 전문 지식을 공유하며 보완적인 강점을 활용하여 빠르게 진화하는 상황에서 경쟁력을 높일 수 있습니다. 혁신적인 암 치료법이 모색되는 가운데, 항체 약물 접합체는 건강한 조직을 온존하면서 암세포를 선택적으로 표적으로 파괴하는 능력을 갖고, 부작용을 최소한으로 억제하는 것으로 주목을 받고 있습니다. 그 결과, 주요 제약 기업과 생명 공학 기업은 항체 약물 접합체의 개발과 상업화를 가속화하기 위해 전략적 제휴를 맺고 있습니다.

시장 경쟁이 치열해짐에 따라 기업은 파이프라인에 유망한 항체 약물 접합체의 기술과 후보를 가진 다른 기업의 인수와 합병을 모색하고 있습니다. 예를 들어, 주요 제약 회사는 항체 약물 접합체의 개발을 전문으로 하는 중소 생명 공학 회사를 인수하고 선진 기술을 기존 제품 라인에 신속하게 통합합니다. 이러한 인수는 인수 기업이 포트폴리오를 강화하고 치료제의 효능 및 안전성 프로파일을 개선할 수 있는 새로운 링커 기술, 페이로드 및 타겟팅 메커니즘에 대한 액세스를 얻는 데 도움이 됩니다. 2024년 10월, GlycoMimetics, Inc.는 고형암 치료를 목적으로 한 암치료제 파이프라인을 추진하는 비상장 생명공학기업인 Crescent Biopharma, Inc.와 인수계약을 체결했습니다. 인수 완료 후, 회사는 Crescent Biopharma, Inc.의 사명으로 사업을 실시할 예정입니다. 2024년 3월, Johnson & Johnson은 독자적인 합성 생물학 기술 플랫폼을 가지고 차세대 항체 약물 접합체의 설계 개발을 실시하는 임상 단계의 바이오 의약품 기업인 Ambrx Biopharma사를 인수했습니다. 2024년 9월, 차세대 항체 약물 접합체의 개발에 종사하는 스위스의 암 및 바이오테크놀러지 기업인 Araris Biotech AG사는 Innate Pharma사와의 계약 체결을 발표했습니다. 이 계약에 따라 Innate는 Araris에 Transglutaminase 결합 기술에 대한 특허 포트폴리오를 양도합니다.

항체 약물 접합체 시장 경쟁 구도은 전략적 투자에 종사하는 주요 기업의 활발한 활동을 특징으로 합니다. 이러한 역동성은 각 회사가 제품의 차별화를 도모하고 시장에서 리더십을 확립하기 위해 노력하면서 기술 혁신과 개선을 촉진하고 있습니다. 암 영역에 대한 자본 투자의 유입은 신규 참가자를 끌어들이고 혁신적인 아이디어를 촉구하는 보다 활기찬 생태계를 가져오고 있습니다. 항체 약물 접합체 시장의 성장을 가속하는데 있어서 M&A, 제휴, 공동 연구를 통한 전략적 투자는 매우 중요한 역할을 하고 있습니다. 이러한 투자는 제품 포트폴리오 강화, 제조 공정 개선, 효과적이고 표적화된 암 치료의 개발을 추진하기 위한 기술 혁신을 촉진함으로써 시너지 환경을 창출하고 있습니다.

경쟁사와의 비교 분석은 제품 포트폴리오(제품 만족도, 제품 특징, 이용가능성), 최근 시장 동향(합병 및 인수, 신제품 출시 및 강화, 투자 및 자금 조달, 수상, 합의, 제휴 및 협력, 인지도, 확대), 경쟁 구도에 대해 보다 나은 의사결정과 이해를 돕는 지역적 존재감에 따라 실시하였습니다. 이 보고서는 세계 항체 약물 접합체 시장에서 주요 벤더의 최근 중요한 동향과 혁신에 대해 깊이 조사했습니다. 주요 시장 진출기업은 ADC Therapeutics SA, Pfizer Inc. AbbVie Inc. 등입니다.

기술에 따라 항체 약물 접합체 시장은 절단성 링커와 비분열성 링커로 구분됩니다. 2023년에는 절단성 링커 부문이 시장에서 가장 큰 점유율을 차지했습니다. 용도별로는 항체 약물 접합체 시장은 혈액암, 뇌종양, 유방암, 난소암, 폐암 등으로 구분됩니다. 2023년에는 유방암 분야가 시장에서 가장 큰 점유율을 차지하고 있습니다.

항체 약물 접합체 시장에서 사업을 전개하는 기업은 다양한 유기적 및 무기적 전략을 채용하고 있습니다. 유기적 전략에는 주로 제품 시장 및 제품 승인이 포함됩니다. 무기적인 성장 전략으로는 인수, 제휴, 파트너십 등이 있습니다. 이러한 성장 전략을 통해 시장 진출기업은 사업을 확대하고 지리적 존재를 높이고 시장 전체의 성장에 기여할 수 있습니다. 또한 인수 및 제휴와 같은 전략은 고객 기반을 강화하고 제품 포트폴리오를 확대하는 데 도움이 됩니다. 항체 약물 접합체 시장의 주요 기업에 의한 중요한 개발의 일부는 다음과 같습니다.

2024년 11월, AstraZeneca는 싱가포르에 항체 약물 접합체(ADC) 전용 15억 달러의 제조 시설을 건설하여 ADC 포트폴리오의 세계 공급을 개선합니다. ADC는 표적 항체를 사용하여 강력한 항암제를 암세포에 직접 투여하도록 설계된 선진적 치료법입니다.

항체 약물 접합체 시장 : 주요 시장 역학
촉진요인
- 주요 기업에 의한 전략적 투자
- 승인 제품 증가
시장 성장 억제요인
- 제조상의 과제
시장 기회
- 새로운 적응증으로의 확대
향후 동향
- 임상시험 파이프라인 확대
촉진요인과 억제요인의 영향

제6장 항체 약물 접합체 시장 : 세계 시장 분석

항체 약물 접합체 시장의 매출액(2021-2031년)
항체 약물 접합체 시장 예측 분석

제7장 항체 약물 접합체 시장 분석 : 기술별

절단성 링커
비분열성 링커

제8장 항체 약물 접합체 시장 분석 : 용도별

혈액암
뇌종양
유방암
난소암
폐암
기타

제9장 항체 약물 접합체 시장 분석 : 표적별

HER2
CD22
CD30
기타

제10장 항체 약물 접합체 시장 분석 : 유통 채널별

소매 약국
병원 약국
온라인 약국

제11장 항체 약물 접합체 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 경쟁 구도

히트맵 분석
기업 점유율 분석

제13장 업계 정세

항체 약물 접합체 시장에서의 성장 전략
유기적 성장 전략
무기적 성장 전략

제14장 기업 프로파일

ADC Therapeutics SA
Pfizer Inc
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Co Ltd
GSK Plc
Gilead Sciences Inc
AstraZeneca Plc
Astellas Pharma Inc
RemeGen Co Ltd
Takeda Pharmaceutical Co Ltd
Merck KGaA
Johnson & Johnson
Bristol-Myers Squibb Co
BioNTech SE
AbbVie Inc

제15장 부록

CSM 25.02.27

The antibody drug conjugates market is expected to reach US$ 38.07 billion by 2031 from US$ 8.10 billion in 2023; the market is estimated to grow at a CAGR of 21.3% during 2023-2031. Major factors driving the market growth include strategic investments by key players and increase in availability of approved products. Further, expansion into new indications is likely to boost the market during the forecast period. However, manufacturing challenges are among the market deterrents.

Strategic investments such as mergers, acquisitions, partnerships, and collaborations among key players in the antibody-drug conjugates (antibody-drug conjugates) market significantly influence its growth and development. These strategies enable companies to pool resources, share expertise, and leverage complementary strengths to enhance their competitive edge in a rapidly evolving landscape. Amid the search for innovative cancer therapies, antibody-drug conjugates have gained attention for their ability to selectively target and destroy cancer cells while sparing healthy tissues, thereby minimizing side effects. Consequently, major pharmaceutical and biotechnology firms are increasingly engaging in strategic alliances to accelerate the development and commercialization of antibody-drug conjugates.

As the market becomes more competitive, companies seek to acquire or merge with other firms that have promising antibody-drug conjugate technologies or candidates in their pipelines. For instance, larger pharmaceutical companies acquire smaller biotech firms specializing in antibody-drug conjugate development to quickly incorporate advanced technologies into their existing product lines. Such acquisitions help the acquiring company enhance its portfolio and gain access to novel linker technologies, payloads, and targeting mechanisms that can improve the efficacy and safety profiles of its therapeutics. In October 2024, GlycoMimetics, Inc. entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. Upon completion of the transaction, the company plans to operate under the name Crescent Biopharma, Inc. In March 2024, Johnson & Johnson acquired Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform, to design and develop next-generation antibody-drug conjugates. In September 2024, Araris Biotech AG, a Swiss oncology and biotechnology company involved in developing next-generation antibody-drug conjugates, announced making an agreement with Innate Pharma. Under the agreement, Innate would assign Araris a portfolio of patents related to its transglutaminase conjugation technology.

The competitive landscape in the antibody-drug conjugates market is characterized by a high level of activity from key players engaging in strategic investments. This dynamism encourages innovation and improvement as companies strive to differentiate their products and establish leadership in the market. The influx of capital investment into oncology attracts new entrants, leading to a more vibrant ecosystem encouraging innovative ideas. Strategic investments through mergers, acquisitions, partnerships, and collaborations play a pivotal role in driving the growth of the antibody-drug conjugates market. These investments create a synergistic environment by enhancing product portfolios, improving manufacturing processes, and fostering innovation to propel the development of effective and targeted cancer therapies.

The comparative company analysis evaluates and categorizes the antibody drug conjugates market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Antibody Drug Conjugates Market. The key market players are ADC Therapeutics SA, Pfizer Inc, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Co Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, Takeda Pharmaceutical Co Ltd, Merck KGaA, Johnson & Johnson, Bristol-Myers Squibb Co, BioNTech SE, AbbVie Inc.

Based on technology, the antibody drug conjugates market is segmented into cleavable linker and non-cleavable linker. In 2023, the cleavable linker segment held the largest share of the market. Based on application, the antibody drug conjugates market is segmented into blood cancer, brain cancer, breast cancer, ovarian cancer, lung cancer and others. In 2023, the breast cancer segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the antibody drug conjugates market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the antibody drug conjugates market are listed below.

In November 2024, AstraZeneca constructed a US$ 1.5 billion manufacturing facility in Singapore dedicated to antibody drug conjugates (ADCs), which will improve the global supply of its ADC portfolio. ADCs are advanced treatments designed to deliver powerful cancer-fighting agents directly to cancer cells using targeted antibodies.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Antibody Drug Conjugates Market Landscape

4.1 PEST Analysis
4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 4.2.2 List of Approved Products
- 4.2.3 Pipeline Analysis
- 4.2.4 Regulatory Guidelines

5. Antibody Drug Conjugates Market - Key Market Dynamics

5.1 Antibody Drug Conjugates Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Strategic Investments by Key Players
- 5.2.2 Increase in Availability of Approved Products
5.3 Market Restraints
- 5.3.1 Manufacturing Challenges
5.4 Market Opportunities
- 5.4.1 Expansion into New Indications
5.5 Future Trends
- 5.5.1 Expanding Clinical Trial Pipeline
5.6 Impact of Drivers and Restraints:

6. Antibody Drug Conjugates Market - Global Market Analysis

6.1 Antibody Drug Conjugates Market Revenue (US$ Million), 2021-2031
6.2 Overview
6.3 Antibody Drug Conjugates Market Forecast Analysis

7. Antibody Drug Conjugates Market Analysis - by Technology

7.1 Cleavable Linker
- 7.1.1 Overview
- 7.1.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Non-cleavable Linker
- 7.2.1 Overview
- 7.2.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibody Drug Conjugates Market Analysis - by Application

8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Brain Cancer
- 8.2.1 Overview
- 8.2.2 Brain Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Ovarian Cancer
- 8.4.1 Overview
- 8.4.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Lung Cancer
- 8.5.1 Overview
- 8.5.2 Lung Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibody Drug Conjugates Market Analysis - by Target

9.1 HER2
- 9.1.1 Overview
- 9.1.2 HER2: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.2 CD22
- 9.2.1 Overview
- 9.2.2 CD22: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.3 CD30
- 9.3.1 Overview
- 9.3.2 CD30: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibody Drug Conjugates Market Analysis - by Distribution Channel

10.1 Retail Pharmacies
- 10.1.1 Overview
- 10.1.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Hospital Pharmacies
- 10.2.1 Overview
- 10.2.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibody Drug Conjugates Market - Geographical Analysis

11.1 Overview
11.2 North America
- 11.2.1 North America Antibody Drug Conjugates Market Overview
- 11.2.2 North America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.3 North America: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.2.3.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.2.4 North America: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.2.4.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.2.5 North America: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.2.5.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.2.6 North America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.6.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.7 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.1 North America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.2.7.2 United States: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.2.1 United States: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.2.2 United States: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.2.3 United States: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.2.4 United States: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.7.3 Canada: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.3.1 Canada: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.3.2 Canada: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.3.3 Canada: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.3.4 Canada: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.2.7.4 Mexico: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.7.4.1 Mexico: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.2.7.4.2 Mexico: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.2.7.4.3 Mexico: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.2.7.4.4 Mexico: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.3 Europe
- 11.3.1 Europe Antibody Drug Conjugates Market Overview
- 11.3.2 Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.3.3 Europe: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.3.3.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.3.4 Europe: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.3.4.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.3.5 Europe: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.3.5.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.3.6 Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.6.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.7 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.1 Europe: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.3.7.2 United Kingdom: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.2.1 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.2.2 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.2.3 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.2.4 United Kingdom: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.3 Germany: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.3.1 Germany: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.3.2 Germany: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.3.3 Germany: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.3.4 Germany: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.4 France: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.4.1 France: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.4.2 France: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.4.3 France: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.4.4 France: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.5 Italy: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.5.1 Italy: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.5.2 Italy: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.5.3 Italy: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.5.4 Italy: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.6 Spain: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.6.1 Spain: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.6.2 Spain: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.6.3 Spain: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.6.4 Spain: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.3.7.7 Rest of Europe: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.7.7.1 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.3.7.7.2 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.3.7.7.3 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.3.7.7.4 Rest of Europe: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.4 Asia Pacific
- 11.4.1 Asia Pacific Antibody Drug Conjugates Market Overview
- 11.4.2 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.4.3 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.4.3.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.4.4 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.4.4.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.4.5 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.4.5.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.4.6 Asia Pacific: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.6.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.7 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.1 Asia Pacific: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.4.7.2 China: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.2.1 China: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.2.2 China: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.2.3 China: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.2.4 China: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.3 Japan: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.3.1 Japan: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.3.2 Japan: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.3.3 Japan: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.3.4 Japan: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.4 India: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.4.1 India: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.4.2 India: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.4.3 India: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.4.4 India: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.5 Australia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.5.1 Australia: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.5.2 Australia: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.5.3 Australia: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.5.4 Australia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.6 South Korea: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.6.1 South Korea: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.6.2 South Korea: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.6.3 South Korea: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.6.4 South Korea: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.4.7.7 Rest of APAC: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.7.7.1 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.4.7.7.2 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.4.7.7.3 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.4.7.7.4 Rest of APAC: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.5 Middle East and Africa
- 11.5.1 Middle East and Africa Antibody Drug Conjugates Market Overview
- 11.5.2 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.5.3 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.5.3.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.5.4 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.5.4.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.5.5 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.5.5.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.5.6 Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.6.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.7 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.1 Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.5.7.2 South Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.2.1 South Africa: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.2.2 South Africa: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.2.3 South Africa: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.2.4 South Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.3 Saudi Arabia: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.3.1 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.3.2 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.3.3 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.3.4 Saudi Arabia: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.4 United Arab Emirates: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.4.1 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.4.2 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.4.3 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.4.4 United Arab Emirates: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.5.7.5 Rest of Middle East and Africa: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.7.5.1 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.5.7.5.2 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.5.7.5.3 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.5.7.5.4 Rest of Middle East and Africa: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
11.6 South and Central America
- 11.6.1 South and Central America Antibody Drug Conjugates Market Overview
- 11.6.2 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
- 11.6.3 South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
  - 11.6.3.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Technology
- 11.6.4 South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
  - 11.6.4.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Application
- 11.6.5 South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
  - 11.6.5.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Target
- 11.6.6 South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.6.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.6.7 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.1 South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast Analysis - by Country
  - 11.6.7.2 Brazil: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.2.1 Brazil: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.2.2 Brazil: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.2.3 Brazil: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.2.4 Brazil: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.7.3 Argentina: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.3.1 Argentina: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.3.2 Argentina: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.3.3 Argentina: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.3.4 Argentina: Antibody Drug Conjugates Market Breakdown, by Distribution Channel
  - 11.6.7.4 Rest of South and Central America: Antibody Drug Conjugates Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.6.7.4.1 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Technology
    - 11.6.7.4.2 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Application
    - 11.6.7.4.3 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Target
    - 11.6.7.4.4 Rest of South and Central America: Antibody Drug Conjugates Market Breakdown, by Distribution Channel

12. Competitive Landscape

12.1.1 Heat Map Analysis
12.1.2 Company Share Analysis:

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Antibody Drug Conjugates Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 ADC Therapeutics SA
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 F. Hoffmann-La Roche Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Daiichi Sankyo Co Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Financial Overview
- 14.4.4 SWOT Analysis
- 14.4.5 Key Developments
14.5 GSK Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Financial Overview
- 14.5.4 SWOT Analysis
- 14.5.5 Key Developments
14.6 Gilead Sciences Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 AstraZeneca Plc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Astellas Pharma Inc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 RemeGen Co Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Financial Overview
- 14.9.4 SWOT Analysis
- 14.9.5 Key Developments
14.10 Takeda Pharmaceutical Co Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
14.11 Merck KGaA
- 14.11.1 Key Facts
- 14.11.2 Business Description
- 14.11.3 Products and Services
- 14.11.4 Financial Overview
- 14.11.5 SWOT Analysis
- 14.11.6 Key Developments
14.12 Johnson & Johnson
- 14.12.1 Key Facts
- 14.12.2 Business Description
- 14.12.3 Products and Services
- 14.12.4 Financial Overview
- 14.12.5 SWOT Analysis
- 14.12.6 Key Developments
14.13 Bristol-Myers Squibb Co
- 14.13.1 Key Facts
- 14.13.2 Business Description
- 14.13.3 Products and Services
- 14.13.4 Financial Overview
- 14.13.5 SWOT Analysis
- 14.13.6 Key Developments
14.14 BioNTech SE
- 14.14.1 Key Facts
- 14.14.2 Business Description
- 14.14.3 Products and Services
- 14.14.4 Financial Overview
- 14.14.5 SWOT Analysis
- 14.14.6 Key Developments
14.15 AbbVie Inc
- 14.15.1 Key Facts
- 14.15.2 Business Description
- 14.15.3 Products and Services
- 14.15.4 Financial Overview
- 14.15.5 SWOT Analysis
- 14.15.6 Key Developments

15. Appendix

15.1 About The Insight Partners